Regular communication with the prescribing clinician is therefore more important than relying on lab testing alone
Clinical trials of FDA-approved GLP-1 medications have shown average weight loss of roughly 15 to 20 percent over about a year, depending on the drug and dose
TGR5, Takeda G protein receptor 5
However, the anti-inflammatory effects of GLP-1 agonists appear to provide benefit beyond what weight loss alone would explain
Throughout, we will interweave clinical trial data, real-world case observations, and perspective from experts to provide a nuanced understanding of how GLP-1 therapies have evolved and what challenges and opportunities lie ahead
This might seem like a low percentage compared to the 1-10% concentrations we have seen in facial products, but the higher concentration can be irritating to more sensitive skin types